Preclinical study suggests combination of AXL inhibitor and erlotinib could induce G2-M cell cycle arrest and enhance apoptosis for NSCLC that was resistant to EGFR-TKIs [41,44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.